Gland Pharma sets November 9 vote: what it means for Gland Pharma stock

Published on 10/20/2026 at 03:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gland Pharma approved USD 21 million on October 1, 2026 for a 60 percent stake. For Gland Pharma stock, completion targets October 31, 2026.

Corporate dates and ownership

Shareholder voting results are due by November 9, 2026.
Gland Pharma approved a USD 21 million investment on October 1, 2026.
The Novelstar transaction targets completion by October 31, 2026.

Gland Pharma, INE068V01023, Illustration mit AI erstellt.

Gland Pharma (ISIN INE068V01023) set November 9, 2026 as the expected result date for shareholder voting on Xingli Wang's appointment. The vote follows a USD 21 million investment approved on October 1, 2026 for a 60 percent stake in Novelstar Pharma, as ScanX reported.

Three dates define the transaction

Novelstar Pharma was incorporated on September 30, 2026, as a newly formed US entity. On October 1, 2026, Gland Pharma approved the USD 21 million cash investment through Gland Pharma USA, which is intended to support expansion in the United States. On October 6, 2026, the postal ballot notice set remote voting from October 7 through November 5, 2026, with results due by November 9, 2026, according to ScanX.

What does 60 percent mean?

The proposed structure would make Novelstar a subsidiary of Gland Pharma USA and a step-down subsidiary of Gland Pharma. Gland Pharma USA would hold 60 percent of Novelstar, while Fosun Pharma USA would hold the remaining 40 percent. Novelstar's post-transaction share capital is expected to reach USD 35 million, but the newly incorporated company had no business or turnover when the plan was announced, TradingView reported.

The transaction therefore adds a defined ownership structure before it adds reported operating revenue. Gland Pharma USA reported turnover of USD 87,342 in fiscal year 2025 and no turnover in fiscal year 2026, according to Free Press Journal.

Next corporate dates

The proposed completion date for the Novelstar transaction is October 31, 2026. The postal ballot results are expected by November 9, 2026, while the appointment of Xingli Wang remains subject to shareholder approval. The dates make the vote and transaction completion the next identifiable milestones for Gland Pharma stock.

Business profile

Gland Pharma is an India-based manufacturer of sterile and complex injectable medicines. It is listed on the National Stock Exchange and Bombay Stock Exchange under the ticker GLAND, and its industry is pharmaceuticals, according to Sharpely.